Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre studyOlga Nigro, Corrado Ficorella, Graziella Pinotti et al.|European Journal of Cancer|2020Cited by 71
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: a multicentre studyOlga Nigro, Corrado Ficorella, Graziella Pinotti et al.|medRxiv|2020Cited by 6
Ovarian Endometrioid Adenocarcinoma With a Yolk Sac Tumor Component in a Postmenopausal Woman: Case Report and Review of the LiteratureJacopo Giuliani, Antonio Frassoldati, Marina Marzola et al.|Clinical Ovarian and Other Gynecologic Cancer|2012Cited by 4
Incidence and predictors of infections in patients with advanced non‐small cell lung cancer treated with checkpoint inhibitor immunotherapies: A monocentric retrospective cohort studyDavide Fiore Bavaro, Domenico Galetta, Francesco Di Gennaro et al.|Scandinavian Journal of Immunology|2023Cited by 4
MA26.02 Upfront or Sequential Strategy for New Generation Anaplastic Lymphoma Kinase (ALK) Inhibitors: An Italian Retrospective Study.Élisa Gobbini, Silvia Novello, Pamela Pizzutilo et al.|Journal of Thoracic Oncology|2018Cited by 1